Commerzbank Ag reaffirmed their buy rating on shares of Qiagen N.V. (NASDAQ:QGEN) in a report issued on Friday morning.

A number of other research analysts have also commented on QGEN. Zacks Investment Research lowered shares of Qiagen N.V. from a hold rating to a sell rating in a research report on Wednesday, April 5th. TheStreet lowered shares of Qiagen N.V. from a b- rating to a c rating in a research report on Monday, April 24th. Deutsche Bank AG reaffirmed a buy rating on shares of Qiagen N.V. in a research report on Tuesday, May 2nd. Evercore ISI upped their price objective on shares of Qiagen N.V. from $30.00 to $31.50 and gave the company an outperform rating in a research report on Thursday, May 4th. Finally, Barclays PLC reaffirmed a buy rating and set a $33.00 price objective on shares of Qiagen N.V. in a research report on Friday, May 5th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $32.28.

Qiagen N.V. (NASDAQ:QGEN) opened at 32.84 on Friday. The company has a 50-day moving average price of $34.00 and a 200-day moving average price of $31.00. The firm has a market capitalization of $7.50 billion, a P/E ratio of 100.43 and a beta of 1.15. Qiagen N.V. has a 1-year low of $24.86 and a 1-year high of $35.26.

Qiagen N.V. (NASDAQ:QGEN) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.30 EPS for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.02. The business had revenue of $349 million during the quarter, compared to analyst estimates of $353.09 million. Qiagen N.V. had a net margin of 5.44% and a return on equity of 10.98%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.24 earnings per share. On average, equities research analysts predict that Qiagen N.V. will post $1.22 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/qiagen-n-v-qgen-receives-buy-rating-from-commerzbank-ag/1465918.html.

A number of hedge funds have recently modified their holdings of the company. Canada Pension Plan Investment Board boosted its stake in shares of Qiagen N.V. by 1,128.0% in the first quarter. Canada Pension Plan Investment Board now owns 481,483 shares of the company’s stock valued at $14,012,000 after buying an additional 442,274 shares in the last quarter. Exane Derivatives boosted its stake in shares of Qiagen N.V. by 427.6% in the first quarter. Exane Derivatives now owns 82,944 shares of the company’s stock valued at $2,413,000 after buying an additional 67,224 shares in the last quarter. Wetherby Asset Management Inc. boosted its stake in shares of Qiagen N.V. by 1.8% in the first quarter. Wetherby Asset Management Inc. now owns 9,273 shares of the company’s stock valued at $269,000 after buying an additional 163 shares in the last quarter. First Mercantile Trust Co. boosted its stake in shares of Qiagen N.V. by 27.3% in the first quarter. First Mercantile Trust Co. now owns 14,593 shares of the company’s stock valued at $422,000 after buying an additional 3,126 shares in the last quarter. Finally, Rehmann Capital Advisory Group purchased a new stake in shares of Qiagen N.V. during the first quarter valued at $207,000. 60.45% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen N.V. Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.